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Abstract: Risperidone is a commonly used medication for the treatment of bipolar disorder 
and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment 
in early onset schizophrenia and as both monotherapy and combination therapy for pediatric 
bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive 
and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young 
patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin 
elevation require consideration when evaluating the risk beneﬁ  t ratio for individual patients. 
Here we review published studies of risperidone for the treatment of bipolar disorder and schizo-
phrenia in children and adolescents to provide practitioners with an overview of published data 
on the efﬁ  cacy and safety of risperidone in these patient populations.
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Introduction
Risperidone is a commonly used second generation antipsychotic agent (SGA) 
recently approved for the treatment of schizophrenia in adolescents, ages 13–17, 
and for the short-term treatment of manic or mixed episodes of bipolar I disorder 
in children and adolescents ages 10–17. It has additional indications for bipolar 
mania and schizophrenia in adults, and irritability associated with autism in chil-
dren and adolescents 5–16 years of age. Risperidone or similar SGAs, either alone 
or in combination with the mood stabilizers lithium, valproic acid carbamazepine, 
serve as ﬁ  rst line treatment options for the treatment of pediatric bipolar disorder 
based on severity and acuteness of the illness (Pavuluri et al 2004b; Kowatch and 
DelBello 2005). Risperidone or similar SGAs are also the mainstay of therapy for 
persons with schizophrenia (Miller et al 2004). From 1996 to 2000, risperidone was 
the most prescribed antipsychotic agent in one large study sample of children and 
adolescents (Patel et al 2005). Although more recent data in pediatric populations 
have not been released, risperidone was the second most prescribed antipsychotic 
agent in the United States after quetiapine by both sales and prescription number 
in 2006 (Lamb 2007) and continues to be widely used in a variety of disorders 
prevalent in childhood and adolescence. Given such wide utilization, risperidone, 
along with other pharmacologic agents used to treat bipolar disorder and schizo-
phrenia in the pediatric and adolescent populations, need to be reviewed in detail to 
allow prescribers, patients, and families to weigh the risks and beneﬁ  ts of treatment. 
The purpose of this article, therefore, is to review available data on the efﬁ  cacy, 
effectiveness, and safety of risperidone in children and adolescents with bipolar 
disorder or schizophrenia.
This review was conducted using the publication databases of PubMed, Medline, 
EMBASE, Psych Abstracts, and 2006–2007 annual meeting abstracts for the American Neuropsychiatric Disease and Treatment 2008:4(1) 56
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Psychiatric Association, American Association of Child and 
Adolescent Psychiatry, American College of Neuropsy-
chopharmacology, College of Psychiatric and Neurologic 
Pharmacists, and International Congress on Schizophrenia 
Research. The terms of search included “risperidone”, 
“risperidone and adolescent”, “risperidone and pediatric”, 
“risperidone and bipolar”, and “risperidone and schizophre-
nia” for studies of children and adolescents with bipolar 
disorder or schizophrenia. Where indicated, the references 
from pertinent articles were tracked further. This method 
allowed the presentation of our most up to date ﬁ  ndings on 
risperidone in these populations. Studies are limited, and 
therefore, despite small sample sizes, ﬁ  ndings are described 
in detail along with tabulation to present a comprehensive 
review to the readers.
Neuropharmacology
Risperidone is an antipsychotic agent with a benzisoxa-
zole chemical structure that has potent dopamine-2 (D2), 
serotonin-2A (5HT2A), and alpha-1 receptor antagonism 
(Gardner et al 2005). Risperidone is classiﬁ  ed by most as 
a second generation or “atypical” antipsychotic agent due 
to its relatively lower propensity to induce extrapyramidal 
side effects at lower doses as compared with ﬁ  rst genera-
tion counterparts like haloperidol. It is a major substrate 
of cytochrome-P450 (CYP450) 2D6 and a minor substrate 
of CYP3A4, with major and mild inhibition of those two 
metabolic enzyme systems, respectively. The half life 
of risperidone is approximately 20–30 hours, with the 
half-life of the active 9-OH-risperidone metabolite being 
21–30 hours. The antipsychotic and antimania effects of 
risperidone are postulated to result from potent dopamine-2 
and serotonin-2A antagonism in the mesolimbic dopamine 
pathway and cerebral cortex, respectively. Risperidone 
has been shown to be effective in the acute and mainte-
nance treatment of schizophrenia and bipolar disorders, 
with emerging evidence in younger patient populations 
reviewed here.
Efﬁ  cacy/effectiveness
Adolescents with schizophrenia
Risperidone has been studied in seven published trials of ado-
lescents with schizophrenia – two open label monotherapy 
studies, two comparisons with olanzapine and haloperidol, 
two comparisons with olanzapine, and one randomized 
double blind placebo-controlled study of two ﬁ  xed doses. The 
studies summarized in Table 1 were conducted in adolescent 
and young adult populations, with ages ranging from 9 to 28 
years and the majority of participants below 20 years of age. 
Primary outcomes are summarized in Table 1.
In 1997, one of the ﬁ  rst formal studies of risperidone in 
adolescents with schizophrenia was published (Armenteros 
et al 1997). This was an open-label, 6-week study of 10 ado-
lescents ages 11–18 with schizophrenia who had undergone a 
2-week washout prior to the initiation of risperidone titrated 
to 0.05–0.104 mg/kg/day (4–10 mg/day). Seven of the 10 
participants had been previously treated with at least one ﬁ  rst 
generation antipsychotic agent. These subjects were a mix 
of paranoid, disorganized, and undifferentiated schizophre-
nia diagnoses with Positive and Negative Symptoms Scale 
(PANSS) total scores averaging 70.7 at the beginning of 
the study. After 6 weeks, total scores were reduced by 19.9 
points. Positive and negative subscale components improved 
5.6 and 7.0 points respectively (all p-values  0.01). Clinical 
Global Impression (CGI) scores improved from an average 
of 4.5 at baseline to 3.1 at endpoint.
Somnolence was reported in eight out of 10 subjects, two 
had dystonic reactions, one had mild orofacial dyskinesia, and 
three required benztropine to treat extrapyramidal symptoms 
(EPS). Weight gain was common, occurring in 8 out of 10 
participants, with details summarized in Table 2. Despite the 
arguably high doses and side effects, none of the subjects 
discontinued the study due to adverse effects. Changes in 
prolactin were not reported.
Zalsman et al published one of the few studies of risperi-
done in predominantly drug naïve patients (Zalsman et al 
2003). This was an open-label, 6-week study of 11 adoles-
cents ages 15.5–20 with schizophrenia who were treated with 
1–4.5 mg/day risperidone (mean maximum dose = 3.14 ± 1.6 
mg/day). After 6 weeks, the initial average PANSS total 
scores were reduced from 103.54 to 77. Positive and negative 
subscale components improved an average of 11.31 and 2.86 
points respectively over the course of the study, which was a 
statistically signiﬁ  cant improvement for the positive subscale 
measure only (p   0.0001). CGI and BPRS improvements 
are summarized in Table 1. Most subjects reported signiﬁ  cant 
somnolence (n = 8/11) and depression (n = 7/11). Akathisia 
was reported in 4 out of 11 participants, dystonia in 2, and 
orthostasis in 5 participants of the study. Eight of 11 reported 
signiﬁ  cant weight gain, ranging from 1 to 19 kg (see Table 
2) over the course of the 6-week trial. Changes in prolactin 
were not reported.
Gothelf et al (2003) reported an open-label, 8-week 
study of 43 adolescents ages 14–20 with schizophrenia 
(Gothelf et al 2003). This was a mixed sample of paranoid, 
disorganized, and undifferentiated subtypes. Thirty-six of Neuropsychiatric Disease and Treatment 2008:4(1) 57
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Table 1 Summary of risperidone treatment studies in children and adolescents with bipolar disorder or schizophrenia
Author (Year)  Diagnosis  Design  Age range  Duration  Efﬁ  cacy/Effectiveness
     (N)   
(Armenteros  Schizophrenia  Open label  11–18 (10)  6 weeks  PANSS, BPRS, CGI assessments
et al 1997)    treatment with      –  PANSS (total score) improvement = 19.9
   risperidone        points  (p    0.001 vs baseline)
         –  BPRS  improvement  = 12.2 points (p = 0.003
           vs  baseline)
         –  CGI  improvement  = 1.4 points (p = 0.007 vs
           baseline)
(Zalsman et al  Schizophrenia  Open label  15.5–20  6 weeks  PANSS, BPRS, CGI assessments
2003)    treatment with  (11)    –  PANSS (total score) improvement = 26.5
   risperidone        points  (p    0.01 vs baseline)
         –  BPRS  improvement  = 13.5 points (p   0.01 
           vs  baseline)
         –  CGI  improvement  = 1.46 (p   0.001 vs 
           baseline)
(Gothelf et al  Schizophrenia  Open label  14–20.5  8 weeks  PANSS assessment
2003)    treatment with  (43)    –  PANSS (total score) improvement at week
   risperidone  (n  = 17),       8  = 16.3 points (risperidone), 10 points
    olanzapine        (olanzapine), and 19.9 points (haloperidol)
   (n  = 19), or        (p   0.001 for effect of time); no differences
    haloperidol        between medication groups (p = 0.99)
   (n  = 7)    
(Mozes et al   Schizophrenia  Open label  9–14 (25)  12 weeks  PANSS, BPRS, CGAS assessments
2006)    treatment with      –  PANSS (total score) improvement at week
   risperidone        12  = 30.4 points (risperidone; p   0.001 vs 
   (n  = 13) or        baseline) and 42.3 points (olanzapine; 
   olanzapine        p    0.001 vs baseline)
   (n  = 12)      –  BPRS improvement at week 12 = 18.2 points 
           (risperidone;  p    0.001) and 23.9 (olanzapine; 
           p    0.001)
          –  CGAS improvement at week 12 = 1.85 
           (risperidone;  p    0.001 vs baseline) and 2.42 
           (olanzapine;  p    0.001 vs baseline)
         –  p    0.24 for all risperidone vs olanzapine 
           comparisons
(van Bruggen  Schizophrenia  Randomized,  16–28 (42)  6 weeks  PANSS assessment
et al 2003)    ﬂ  exible dose      –  PANSS (total score) improvement at week 6 
   treatment  of        = 15.0 points (risperidone; p   0.05 vs 
    risperidone 1–        baseline) and 15.1 points (olanzapine;
   8  mg/day  (n  = 24)       p    0.05 vs baseline) 
    or olanzapine      –  No signiﬁ  cant differences between treatment 
   5–30  mg/day        groups
   (n  = 18)      
(Sikich et al  Schizophrenia  Randomized,  8–19 (50)  8 weeks  BPRS-C, CGI-I, and CPRS assessments
2004)  spectrum  double blind       –  BPRS-C improvement = 27 points 
 (n  = 26), and  ﬂ  exible dose         (risperidone; p = 0.0018 vs baseline), 28 points
  psychosis  study of         (olanzapine; p = 0.0018 vs baseline), and 16 
  spectrum  risperidone         points (haloperidol; p = 0.012 vs baseline)
 affective  4.0  ± 1.2       –  CPRS (total) improvement = 54 points 
  disorders  mg/day         (risperidone; p = 0.0018 vs baseline), 52 points
 (bipolar  (n  = 19),         (olanzapine; p = 0.0036 vs baseline), and 40 
  disorder  olanzapine         points (haloperidol; p = 0.285 vs baseline)
 or  major  12.3  ± 3.5       –  CGI Improvement = 1.9 points (risperidone;
 depressive  mg/day  (n  = 16)         p = 0.0018 vs baseline), 2.0 points (olanzapine;
  disorder with  or haloperidol         p = 0.0018 vs baseline), and 1.3 points 
 psychotic  5.0  ± 2.0         (haloperidol p = 0.075 vs baseline)
 features;  n  = 24) mg/day  (n  = 15)      –  No statistically signiﬁ  cant differences between
            treatment groups for any outcomes
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Table 1 (Continued)
Author (Year)  Diagnosis  Design  Age range  Duration  Efﬁ  cacy/Effectiveness
     (N)   
(Haas et al   Schizophrenia  Randomized,   13–17 (160)  6 weeks  PANSS assessment
2007)   double  blind,     –  Placebo  improvement  = 8.9 points
    placebo-      –  Risperidone 1–3 mg/day improvement = 21.3 
   controlled        points
    study of      –  Risperidone 4–6 mg/day improvement = 21.2 
   placebo        points
   (n  = 15),     –  Risperidone (either dose range) improvement  
    risperidone 1–        placebo (p   0.001)
   3  mg/day       
   (n  = 55), or         
   risperidone  4–       
   6  mg/day     
   (n  = 51)    
(Frazier et al   Bipolar disorder  Retrospective   4–17 (28)  0.25–34   CGI-Severity assessments
1999)    study of    months  –  CGI-Severity Mania score improvement = 2.5 
    risperidone         points (p   0.01 vs baseline)
   1.7  ± 1.3      –  CGI-Severity Aggression score improvement 
   mg/day        = 2.1 points (p   0.01 vs baseline) 
(Biederman et al   Bipolar disorder  Open-label   4–6 (31)  8 weeks  YMRS, BPRS, CDRS
2005a)    study of      –  YMRS score improvement = 18.8 points 
   risperidone        (risperidone;  p    0.05 vs baseline), 12.1 points 
   0.25–2.0        (olanzapine;  p    0.05 vs baseline)
   mg/day  (n  = 16)      –  BPRS score improvement = 13.1 points 
    or olanzapine        (risperidone; p   0.05 vs baseline), 8.9 points 
   1.25–10        (olanzapine;  p    0.05 vs baseline)
   mg/day  (n  = 15)      –  CDRS score improvement = 12.7 points 
           (risperidone;  p    0.05 vs baseline), 8.3 points 
           (olanzapine;  p  = NS vs baseline)
         –  p  = NS between treatment groups for primary 
           outcomes
(Biederman et al   Bipolar disorder  Open label   6–17 (30)  8 weeks  YMRS, BPRS, and CDRS assessments
2005b)    study of      –  YMRS score improvement = 14.4 points 
   risperidone        (p    0.0001 vs baseline)
    0.25–4.0      –  BPRS score improvement = 12.6 points 
   mg/day        (p  = 0.0002 vs baseline)
          –  CDRS score improvement = 10.2 points 
           (p  = 0.0001 vs baseline)
(Pavuluri  Bipolar disorder  Open label study  5–18 (37)  6 months  YMRS and CGI-BP assessments
et al 2004a)    of risperidone      –  YMRS score improvement = 23.53  
   0.25–3  mg/day+       (risperidone  + lithium), 22.0
   lithium  0.6–1.0          (risperidone  + divalproex sodium)
    mEq/day or divalproex        (p   0.0001 for effect of time;
   sodium  50–120  µg/mL        p  = NS between treatments)
          –  CGI-BP score improvement = 3.56
           (risperidone  + lithium) and 3.82
           (risperidone  + divalproex sodium)
           (p    0.001 for effect of time;
           p  = NS between treatments)
Abbreviations: PANSS, (Positive and Negative Symptoms Scale); BPRS, (Brief Psychiatric Rating Scale); CGI, (Clinical Global Impression Scale – Improvement); CGAS, 
(Children’s Global Assessment Scale); BPRS-C, (Brief Psychiatric Rating Scale for Children); CPRS, (Children’s Psychiatric Rating Scale);   YMRS, (Young Mania Rating Scale); 
CGI-BP, (Clinical Global Impression Scale for Bipolar Disorder); CDRS-R, (Child Depression Rating Scale-Revised).Neuropsychiatric Disease and Treatment 2008:4(1) 59
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these patients had been previously treated with antipsychotic 
agents, differentiating this sample from the previously 
described predominantly treatment-naïve group. Participants 
in this investigation were treated with risperidone (3.3 ± 1.1 
mg/d), olanzapine (12.9 ± 3.1 mg/day), or haloperidol 
(8.3 ± 3.8 mg/day). Thirty-nine of the 43 subjects com-
pleted the trial, with discontinuations due to non-response 
or non-compliance. Baseline PANSS total scores averaged 
90.2, 71.6, and 86.1 for the risperidone, olanzapine, and 
haloperidol treatment groups respectively. Improvements 
averaged 16.9, 13.9, and 19.7 points for the three groups. 
Positive symptoms improved 4.6, 3.3, and 7.2 points, with 
negative symptoms improving 3.9, 4.3, and 4.3 points for ris-
peridone, olanzapine and haloperidol, respectively. Although 
all treatments signiﬁ  cantly improved symptoms over time, 
there were no differences in improvement across the three 
medication groups.
Approximately 3–5 subjects reported inner restlessness, 
increased need for sleep, increased salivation, micturition 
disturbances, polyuria or polydypsia, and dizziness or ortho-
stasis. A separate publication was reported on the weight 
gain incurred in these subjects after 12 weeks of treatment 
(Ratzoni et al 2002). Increases in weight were 3.9 ± 4.8 kg, 
7.2 ± 6.3 kg, and 1.1 ± 3.3 kg for risperidone, olanzapine, 
and haloperidol-treated subjects. Olanzapine subjects gained 
signiﬁ  cantly more weight than risperidone and haloperidol 
groups. Extreme weight gain, deﬁ  ned according to FDA 
criteria as  7% increase from baseline was greatest in the 
olanzapine group (90.5% of olanzapine group), followed by 
risperidone (42.9% of risperidone group) and haloperidol 
(12.5% of haloperidol group). On further analysis, these 
investigators determined that the majority of weight gained 
from the second generation antipsychotics occurred in the 
ﬁ  rst four weeks of treatment (6.45% for olanzapine and 4.5% 
for risperidone).
A subsequent study aimed to further compare risperidone 
and olanzapine in early onset schizophrenia was published 
in 2006 (Mozes et al 2006). This was a 12-week, open label, 
randomized study of risperidone (maximum dose range 
0.5–4.5 mg/day) versus olanzapine (maximum dose range 
5–20 mg/day) in 25 children with child-onset schizophrenia 
ages 9–14 years. Ten subjects had diagnoses of schizophreni-
form disorder, 7 disorganized schizophrenia, 6 paranoid, 
and 2 with diagnoses of schizophrenia with unspeciﬁ  ed 
subtypes. One olanzapine subject and 4 risperidone treated 
subjects dropped out of the trial. Three of the risperidone 
discontinuations were due to lack of improvement with the 
other due to severe hyperprolactinemia (55 ug/L). Baseline 
Table 2 Weight gain
Reference  Study  Population  Sample size  Mean  Mean maximum  Weight gain
  duration    (# on risperidone  age (SD)  (or endpoint)  kg (SD)
  (wks)    if comparison trial)    daily dose (SD)
(Armenteros et al 1997)  6  Schizophrenia  10  15.10 (1.90)  6.6 (1.56)  4.85 (NA)
(Zalsman et al 2003)  6  Schizophrenia  11  17.27 (1.27)  3.14 (1.6)  8.66 (6.53)
(Ratzoni et al 2002)  12  Schizophrenia-spectrum  21  17.21 (2.1)  3.2 (1.1)  3.9 (4.8)
    and conduct disorder
(Mozes et al 2006)  12  Schizophrenia  13  10.71 (1.43)  1.62 (1.02)  4.45 (2.87)
(van Bruggen et al 2003)  6  Schizophrenia  26  20.6 (3.0)  4.4 (1.5)  4.5 (5.2)
(Sikich et al 2004)  8  Schizophrenia-spectrum  19  14.6 (2.9)  4.0 (1.2)  4.9 (3.6)
    and mood disorder with
   psychosis
(Biederman et al 2005b)  8  Bipolar  30  10.1 (2.5)  1.25 (1.5)  2.1 (2.0)
(Biederman et al 2005a)  8  Bipolar  16  5.3 (0.8)  1.4 (0.5)  2.2 (0.4)
(McDougle et al 1997)  12  Pervasive developmental  18  10.2 (3.7)  1.8 (1.0)  8.1 (3.4)
   disorders
(Malone et al 2002)  24  Autism  22  7.1 (3.3)  1.8 (1.1)  3.3 (1.7)
(Findling et al 2000)  10  Conduct disorder  10  9.2 (2.9)  0.75–1.5  4.2 (0.7)
(Gaffney et al 2002)  8  Tourette’s  9  10.4 (2.7)  1.5 (0.9)  2.1 (2.3)
(Aman et al 2002)  6  Disruptive Behaviorsa  55  8.7 (2.1)  2.2 (1.8)  1.16 (0.57)
(Snyder et al 2002)  6  Conduct and disruptive  53  8.6 (0.26)  0.98 (0.06)  2.2 (NA)
   disordersb
(McCracken et al 2002)  8  Autism  49  8.8 (2.7)c  1.8 (0.7)  2.7 (2.9)
aDisruptive behaviors: oppositional deﬁ  ant disorder ± ADHD, conduct disorder ± ADHD, disruptive behavior NOS ± ADHD.
bConduct disorder ± AHDD, oppositional deﬁ  ant disorder  ±  ADHD
cMean (SD) for entire study sample (risperidone + placebo).
Abbreviations: NA, Not available; NOS, Not otherwise speciﬁ  ed.Neuropsychiatric Disease and Treatment 2008:4(1) 60
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PANSS total scores averaged 93.85 and 92.75 for the 
risperidone and olanzapine groups respectively. Improve-
ments in PANSS total scores averaged 30.41 and 42.25 points 
for the two groups. Positive scores improved an average of 
11.61 and 13.3 points for risperidone and olanzapine-treated 
participants, respectively. Negative symptoms improved 
an average of 4.23 and 8.75 points for the two groups. All 
PANSS measures, along with Brief Psychiatric Rating Scale 
(BPRS) and Children’s Global Assessment Scale (CGAS) 
scores improved signiﬁ  cantly (p   0.001) for both treatment 
groups, with no statistical differences observed between 
groups for this study when continuous change scores were 
considered. When the two treatment groups were compared 
to examine differences between groups improving at least 
50% on PANSS negative scores, there was a trend towards 
greater improvement in the olanzapine group (p = 0.047), 
but this was not signiﬁ  cant after correcting for multiple 
comparisons. The risperidone treatment group reported more 
extrapyramidal side effects than the olanzapine group, with 
 30% of risperidone-treated subjects assessed as having 
changes in gait, arm dropping, elbow rigidity, and wrist 
rigidity according to the Barnes Akathisia Rating Scale and 
the Simpson Angus Scale. Mean weight gain was not sig-
niﬁ  cantly different between the risperidone and olanzapine 
groups respectively, with both groups gaining signiﬁ  cant 
weight from baseline as summarized in Table 2.
In another randomized open-label study, symptom 
response and side effects of risperidone and olanzapine were 
compared in 44 children and adolescents ages 16–28 years 
with schizophreniform, schizophrenia, or schizoaffective 
disorders (van Bruggen et al 2003). Subjects were assigned 
to risperidone (mean endpoint dose = 4.4 ± 2.9 mg/day) or 
olanzapine (mean endpoint dose = 15.6 ± 3.1 mg/day) in a 
ﬂ  exible titration dosing scheme for this 6-week study. Base-
line PANSS total scores were 89.2 and 90.7 for the risperi-
done and olanzapine groups, respectively. Improvements in 
PANSS total scores averaged 15.0 and 15.1 points for the two 
groups. On average, positive symptoms improved 5.5 and 3.2 
points for the risperidone and olanzapine groups. Negative 
symptoms improved 2.4 and 4.3 points, respectively. There 
were not statistically signiﬁ  cant differences in clinical out-
comes as assessed by the PANSS total or subscale measures, 
percent of patients achieving remission, or time to treatment 
response between the two medication groups.
A signiﬁ  cant number of side effects were reported in 
this study. Greater than 30% of risperidone-treated subjects 
reported somnolence (68.4%), excessive thirst (52.6%), 
decreased libido (52.6%), excessive appetite (42.1%), 
akathisia (31.6%), and dizziness (31.6%). Somnolence, 
thirst, and libido were adverse events reported more often 
in risperidone-treated participants than olanzapine-treated 
subjects. Headache was reported signiﬁ  cantly more often in 
the olanzapine (33.3%) than the risperidone (5.3%) group. 
Weight gain averaged 4.5 ± 5.2 kg in the risperidone group 
and 3.6 ± 3.8 kg in the olanzapine group. There were no 
signiﬁ  cant differences in weight gain observed. Prolactin 
was not examined in this investigation. Furthermore, the 
relationship between adjunctive medications and side 
effects was not reported. However, 16% of the risperidone 
group and 0% of the olanzapine group were taking antide-
pressants, 32% of risperidone and 39% of olanzapine group 
were taking benzodiazepines, and 28% of risperidone and 
11% of olanzapine participants were taking anticholinergic 
medications. The side-effect proﬁ  les of these medications 
in addition to the antipsychotics may have accounted for 
the unusually high rates of some of the reported adverse 
events and warrants consideration when interpreting the 
results of this study.
Fifty psychotic youths, 52% with schizophrenia spec-
trum disorders and 42% with a psychotic mood disorder, 
were treated in a randomized double blind 8-week trial of 
risperidone (4.0 ± 1.2 mg), olanzapine (12.3 ± 3.5 mg), and 
haloperidol (5.0 ± 2.0 mg) (Sikich et al 2004). Participants 
ranged from 8–19 years of age. Dosing was done in a ran-
domized, ﬁ  xed dose, parallel design for the 8-week treatment 
period. Because of the mix of schizophrenia spectrum and 
mood disorders, the PANSS was not administered. Baseline 
BPRS-C scores averaged 54, 50, and 49 for the risperidone, 
olanzapine, and haloperidol treatment groups respectively. 
Mean BPRS-C improvements were 27, 28, and 16 points 
for the three groups. Child Psychiatric Rating Scale (CPRS) 
positive-symptom scores improved 13, 19, and 14 points 
for the three groups, while CPRS-negative symptom scores 
improved 12, 6, and 7 points for risperidone, olanzapine, 
and haloperidol respectively. Changes in scores over time, 
percent responders at week 8, and percent of subjects in each 
treatment group have a CGI value of “1” at the end of the 
study were all similar across treatments.
Fifty-three percent of the risperidone-treated group 
required low dose benztropine for the management of EPS. 
This was similar to the 53% and 67% of olanzapine and 
haloperidol-treated participants who also required anticho-
linergic treatment. At the end point of the study, sedation 
(26%) and headache (31%) were the two most commonly 
reported side effects for the risperidone group. However, 
over 30% of risperidone-treated subjects reported sedation Neuropsychiatric Disease and Treatment 2008:4(1) 61
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(89%), blurry vision (42%), dry mouth (32%), nervousness 
(53%), headache (62%), drooling (32%), light headedness 
(37%), nausea (53%), weakness (32%), constipation (32%), 
musculoskeletal pain (42%), or sweats/chills (32%) at one 
point or another throughout the course of the trial. Signiﬁ  cant 
differences between treatment groups in side effects at end 
point included the haloperidol group reporting more dry 
mouth and decreased coordination at any point, lightheaded-
ness, and sweats/chills at termination. Adjunctive medica-
tions were allowed in this study including anticholinergics, 
beta blockers, benzodiazepines, antidepressants, and mood 
stabilizers but did not differ signiﬁ  cantly between treatment 
groups. As mentioned in the context of the previous study, 
the number of concomitant medications may have artiﬁ  cially 
elevated the percentage of subjects reporting various adverse 
events at various points throughout the course of the study. 
Weight gain averaged 4.9 ± 3.6 kg, 7.1 ± 4.1 kg, and 3.5 ± 3.7 
kg for the risperidone, olanzapine, and haloperidol groups, 
respectively, which was statistically different across groups. 
Prolactin levels for all groups were mildly elevated at base-
line (34.1 ± 21.11 ng/mL risperidone, 31.5 ± 25.8 olanzapine, 
and 28.8 ± 27.4 haloperidol). Prolactin elevations did not 
signiﬁ  cantly vary from baseline after the 8-week treatment 
period for any of the three treatment groups, although prior 
treatments that may have inﬂ  uenced the elevated levels at 
baseline were not described.
The most recent research regarding the efﬁ  cacy and safety 
of risperidone in the treatment of schizophrenia in adolescents 
was reported at the 2007 American Psychiatric Association 
Annual Meeting (Haas et al 2007). This was a double blind, 
randomized, placebo-controlled study of 2 ﬁ  xed-dose strata 
of risperidone (1–3 mg/day and 4–6 mg/day). A total of 269 
patients 13–17 years of age were randomized to placebo 
(n = 160), risperidone 1–3 mg/day (n = 55), or risperidone 
4–6 mg/day (n = 54) for 6 weeks. PANSS total score improve-
ments averaged 21.3, 21.2, and 8.9 points for the risperidone 
1–3 mg, 4–6 mg, and placebo groups, respectively. No dif-
ferences were observed between the two dose strata and the 
authors concluded that the lower dose range had the best risk 
beneﬁ  t proﬁ  le for use in this population. Details of adverse 
events were not given in detail in the published abstract.
Children and adolescents with bipolar 
disorder
Risperidone has been studied in 4 prospective studies in 
pediatric bipolar disorder study samples, with additional data 
on safety and effectiveness published in retrospective and 
case studies. The studies summarized in Table 1 include those 
done in adolescent and young adult populations, with ages 
ranging from 4–18 years. As is the case with the treatment 
of adults with bipolar disorder, the majority of children and 
adolescents with bipolar 1 or bipolar disorder not otherwise 
speciﬁ  ed require more than one medication for symptom 
management. Therefore it is not surprising that two of the 
four prospective studies involve the analysis of risperidone 
in combination with other mood stabilization medications. 
Primary outcomes are summarized in Table 1.
In 1999, the ﬁ  rst study of using risperidone to treat 
juveniles with bipolar disorder was published (Frazier et al 
1999). This was a retrospective chart review of a well char-
acterized population of 28 youths ages 4–17 years treated 
for an average of 6.1 ± 8.5 months (range = 0.25–34 months) 
with an average dose of 1.7 ± 1.3 mg/day of risperidone. As 
is commonly observed in clinical practice, the number of 
patients with comorbid diagnoses was high, with an aver-
age of 2.6 ± 0.8 additional psychiatric diagnoses per per-
son. This included attention deﬁ  cit hyperactivity disorder 
(ADHD), oppositional deﬁ  ant disorder (ODD), pervasive 
developmental disorder (PDD), language disorder, anxiety 
disorder, conduct disorder, obsessive compulsive disorder 
(OCD), and post traumatic stress disorder (PTSD). Accord-
ingly, many other concomitant medications were also being 
used in this population, including stimulants (71%), alpha 
agonists or beta blockers (71%), mood stabilizers (64%), 
serotonin reuptake inhibitors (43%), tricyclic antidepres-
sants (43%), first generation antipsychotics 32%), or 
benzodiazepines (7%). The primary assessment of effec-
tiveness in these patients was the CGI stratiﬁ  ed by speciﬁ  c 
syndromes (eg, mania, ADHD, psychosis, or aggression). 
After the addition of risperidone to the treatment regimens 
of these patients, the CGI-mania scale scores decreased 
2.5 points from the baseline mean of 5.4 ± 1.0, the CGI-
aggression scores decreased 2.1 points from the baseline 
mean of 5.1 ± 1.2, psychosis symptoms declined 2.1 points 
from the baseline mean scores of 3.6 ± 0.4, and the ADHD 
component scores decreased an average of 0.7 points from 
the baseline mean of 5.0 ± 0.8. All changes in subscale 
measures signiﬁ  cantly improved (p   0.01), although the 
improvements in ADHD-speciﬁ  c symptoms were not as 
clinically robust as those observed on other subscales.
Weight gain was reported for 18% of the patients, 
although the speciﬁ  c amounts gained were not reported. In 
this sample, sedation was the other side effect, reported at 
18%. Prolactin levels were available for 11 of the children, 
nine of whom had elevations above normal limits, with an 
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Recently, Saxena et al published a case series of 4 
boys and 2 girls ages 5–15 with pediatric bipolar disorder 
(Saxena et al 2006). The goal of this study was to evaluate 
the effectiveness of risperidone in this population of patients 
who had failed to adequately respond to other mood stabi-
lizers, primarily divalproex sodium. The clinical scenarios 
of the cases presented are representative of many patients 
seen in clinical practice where initial treatments fail to 
adequately treat aggressive symptoms. In these patients, the 
mean dose of risperidone was 0.85 mg/day and was added 
on to therapeutic doses of existing medications that included 
mood stabilizers, low dose antidepressants, and low dose 
stimulants. In all of the patients included in this case series, 
symptoms of aggression were greatly reduced after the addi-
tion of risperidone. One patient had akathisia at a dose of 
0.25 mg in the morning, which was relieved after removing 
the medication and re-starting at different a.m./p.m. dosing 
schedule. One patient had the dose reduced due to possible 
cognitive impairment. No subjects in this report permanently 
discontinued risperidone due to side effects.
Biederman et al (2005a) recently conducted an open label 
8-week monotherapy trial of risperidone (1.25 ± 1.5 mg/day) 
in 30 children and adolescents 6–17 years of age with bipolar 
disorder (Biederman et al 2005a). Additional treatment with 
antidepressants, mood stabilizers, other antipsychotics, or 
anticonvulsants was not permitted for this investigation. 
The Young Mania Rating Scale (YMRS), BPRS, and CDRS 
were the primary outcomes reported. Twenty-two of the 30 
participants completed the entire 8-week study, with drop-
outs primarily due to lack of efﬁ  cacy and lack of follow-up 
(7 participants) and one due to orthostatic hypotension. The 
baseline YMRS total scores were in the severe range at 
27.9 ± 9.1 and decreased signiﬁ  cantly (p   0.0001) from 
an average of 14.4 points to 13.5 ± 9.7 at endpoint. BRPS 
total scores decreased an average of 12.6 points over the 
course of study, with signiﬁ  cant improvements on resistance 
(mania symptoms) and positive symptoms, but not negative 
symptoms or anxiety/dayepression components of the scale. 
CDRS scores decreased 10.2 points, from baseline scores of 
40.9 ± 11.5 to 30.7 ± 11.0, which was a signiﬁ  cant improve-
ment (p   0.0001).
This research group also conducted a similar study in 
a younger patient population with an open-label, 8-week 
trial comparing risperidone (1.4 ± 0.5 mg/day) to olanzapine 
(6.3 ± 2.3 mg/day) in 31 children 4–6 years of age with a 
diagnosis of pediatric bipolar disorder (Biederman et al 
2005b). This study did not allow the utilization of other 
antimanic, mood stabilizing, or antidepressant medications. 
The YMRS and CGI mania scales were the primary 
outcome measures for the study. Of the 16 risperidone and 
15 olanzapine-treated subjects, 6 olanzapine and 1 ris-
peridone subjects discontinued before the 8-week endpoint. 
Discontinuations were largely due to lack of efﬁ  cacy (4/7 
subjects). The baseline YMRS total scores for the risperi-
done and olanzapine groups were 35.2 ± 8.2 and 34.2 ± 6.4 
and decreased signiﬁ  cantly (p   0.001) by an average of 
18.3 and 12.1 points over the course of 8 weeks. The dif-
ference between improvements seen in the two treatment 
groups was not statistically signiﬁ  cant for YMRS measures. 
Improvement on CGI measures was subsequently assessed 
categorically, by examining the number of patients in each 
treatment arm who were rated as “much” or “very much” 
improved. The proportion of subjects meeting this criteria 
was 69% and 53% (p = 0.9) for the risperidone and olanzap-
ine treatment groups, respectively. Spontaneously reported 
side effects were not statistically different between the two 
treatment groups. Side effects occurring in greater than 
30% of participants in one or both treatment groups were 
increased appetite, cold/allergies/infection, and headache. 
Both groups gained weight, with an average of 2.2 ± 0.4 kg 
in the risperidone group and 3.2 ± 0.7 kg in the olanzapine 
group. The groups did not differ signiﬁ  cantly in the amount 
of weight gained. Of the vitals biochemical measures col-
lected, including lipid panel, glucose, and prolactin, the 
extent of prolactin elevation was greater in the risperidone 
group (mean increase of 35.7 ng/mL) than the olanzapine 
group (mean increase of 11.9 ng/mL).
Pavuluri et al (2004) conducted an open-label trial of 37 
pediatric bipolar subjects with mania ages 5–18 who were 
sequentially assigned to risperidone (0.75 ± 0.75 mg/day) 
plus divalproex sodium (106 µg/dayL) or lithium (0.9 mEq/L) 
for 6 months (Pavuluri et al 2004a). Primary outcomes were 
assessed via improvements on the YMRS and CGI-Severity 
mania scales. Baseline YMRS scores were 28.8 ± 4.35 and 
30.0 ± 3.69 for the risperidone + lithium and risperidone + 
divalproex sodium groups, respectively. These scores 
improved signiﬁ  cantly over time for both groups, with 
YMRS score reductions averaging 23.53 and 22.0 points 
for the risperidone + lithium and risperidone + divalproex 
sodium groups, respectively. Differences between groups 
were not statistically signiﬁ  cant. Baseline CGI-BP Mania 
subscales averaged 5.35 ± 1.41 and 5.70 ± 0.87 with mean 
improvements of 3.56 and 3.82 points for the two groups. 
Weight gain was the only side effect observed in  30% of 
participants (35.3% lithium + risperidone; 40% divalproex 
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sedation (23.5%, 20%), nausea (23.5%, 15%), increased 
appetite (23.5%, 20%), and stomach pain (23.5%, 10%).
Side effects and tolerability
Risperidone is classiﬁ  ed by most as a second generation or 
“atypical” antipsychotic agent, a class so named for their 
lower propensity to induce movement-related side effects like 
EPS and tardive dyskinesia than older ﬁ  rst generation agents. 
Although speciﬁ  c criteria for antipsychotic “atypicality” are 
still debated, signiﬁ  cant afﬁ  nity of these agents to 5HT2A 
receptors in the mesocortical and nigrostriatal dopamine 
tracks is one common feature, which is thought to facilitate 
the release of dopamine in these areas, thus counteracting 
the negative effects resulting from D2 blockade in these 
regions. This is one proposed mechanism for lower EPS 
rates in these agents as compared to their ﬁ  rst generation 
counterparts. Of the second generation agents, risperidone 
has the highest afﬁ  nity to D2 receptors and as mentioned in 
the previous study reviews of risperidone in young patients 
with schizophrenia and bipolar disorder some patients do 
develop EPS, resulting in medication discontinuation or 
adjunctive treatment with anticholinergic or beta-blocking 
agents for EPS. Potent D2 blockade also results in prolac-
tin elevation, which is more signiﬁ  cant after risperidone 
administration than for any other ﬁ  rst or second generation 
agent. Finally, one of the most problematic side effects of 
risperidone, as well as other second generation agents like 
olanzapine, quetiapine, and clozapine is weight gain. The fol-
lowing section will brieﬂ  y summarize possible mechanisms 
of action for these three broad classes of side effects that are 
highly relevant for risperidone. While other adverse effects 
such as somnolence, sedation, and upset stomach are also 
important, EPS, prolactin elevation, and weight gain may 
have long term health consequences for persons having to 
take medications like risperidone indeﬁ  nitely.
EPS
Early-onset EPS usually appear within the ﬁ  rst 4 weeks 
of antipsychotic treatment and include dystonia, akathisia, 
and parkinsonism. The dopamine-acetylcholine balance 
hypothesis is one theory of antipsychotic-induced EPS. 
An equilibrium of dopaminergic (inhibitory) and cholin-
ergic (excitatory) neuronal activity in the corpus striatum 
is required for normal motor functioning. Dopamine 
blockade by antipsychotics leads to a decrease of dopa-
mine and a subsequent relative increase in acetylcholine 
that results in signs and symptoms of EPS (Marsden and 
Jenner 1980). EPS is a dose-dependent phenomenon. In 
adults taking risperidone, the rates of EPS at doses  6 
mg/day approach those seen with haloperidol, which is 
why clinical recommendations for adults suggest not dosing 
above 4–6 mg/day. This speciﬁ  c relationship has not been 
formally described in children and adolescents, although 
data presented earlier in this review suggests a similar 
dose-response correlation. In the previously presented 
studies, the percentage of patients reporting dystonic reac-
tions ranged from 0%–20%, with the highest rate (20%) 
reported in the small study sample where doses averaged 
6.6 mg/day. The percent of patients presenting with EPS, 
including parkinsonism, akathisia, or dyskinesias, ranged 
from 0%–61.5% in these studies. Interestingly, the highest 
rate of overall EPS, 61.5% was reported in a study where 
the average dose was 1.62 mg/day risperidone. Ascertain-
ment with the SAS and BARS scales may have increased 
the recognition of subtle effects in these participants that 
were perhaps not as recognized in other studies relying on 
generic side effect assessment scales or spontaneous report. 
Concomitant anticholinergic medications often confound 
our abilities as clinicians to recognize the true rate of EPS, 
although in these studies, anticholinergics were generally 
administered after the observation of such effects. Figure 1 
presents a rough assessment of this relationship by plotting 
mean daily dose of risperidone by percentage of patients 
receiving anticholinergic medications in monotherapy trials. 
Recognizing the limitations that age differences, duration 
of treatment, and previous medications may have on the 
likelihood of a given patient needing adjunctive treatment 
for EPS, we can see that doses above 3 mg/day result in 
18%–67% of patients requiring anticholinergic medica-
tions. This is quite robust given the “atypical” designation 
of risperidone.
The potential for EPS from risperidone is a signiﬁ  cant 
consideration for patients and families. EPS can lead to 
stigmatization of children and adolescents, which may affect 
their ability to interact with peers. Tremors and akathisia 
may disrupt learning if not adequately managed, due to 
interference with writing and ability to perform ﬁ  ne motor 
movements as well as the ability to sit still in class. Anti-
cholinergic medications are well known for their propensity 
to cause dry mouth, constipation, confusion, and cognitive 
impairment. Therefore these adverse effects of the medica-
tions used to manage adverse effects of risperidone also war-
rant close monitoring. Pre-treatment and routine follow-up 
monitoring of EPS as well as tardive dyskinesia assessments 
are warranted before starting any antipsychotic agent and 
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all relatively short-term trials, where tardive dyskinesia was 
not observed. However, the high incidence of EPS suggests 
that the long term monitoring for this late-onset movement 
side effect is warranted.
Prolactin elevation
Prolactin is secreted by the anterior pituitary and is involved in 
many physiological processes. Prolactin elevation inhibits the 
hypothalamic-pituitary axis, suppresses gonadotropin-releasing 
hormone release from the hypothalamus, and eventually reduces 
estrogen and testosterone in males and females (Petty 1999). 
Modest elevations induced by antipsychotic agents have been 
associated with amenorrhea, hirsutism, galactorrhea, decreased 
libido, and hypogonadism in women and decreased libido and 
reduced spermatogenesis in males (Howes and Smith 2002).
Dopamine signaling through D2 receptors located on the 
lactotrophs of the anterior pituitary, slows prolactin gene 
transcription and modulates prolactin release. Reducing 
D2 transmission results in a disinhibition of this negative 
feedback mechanism, which elevates prolactin. D2 receptor 
blockade is the primary mechanism of action for antipsy-
chotic medications like risperidone. Agents with the highest 
binding afﬁ  nities for D2 (eg, risperidone) result in the most 
substantial increases in prolactin levels as a result of therapy 
(Dickson and Glazer 1999).
Prolactin elevation occurs in patients irrespective of 
psychiatric diagnosis. When patients ﬁ  rst begin conventional 
APs or risperidone, a substantial spike in prolactin levels is 
commonly seen that persists for 4–6 weeks until stabiliza-
tion occurs (Kinon et al 2003). For some, levels will return 
to just above normal. For others levels remain signiﬁ  cantly 
elevated, putting them at risk for prolacin-related sequelae. 
Investigations in patients taking risperidone  6 weeks 
consistently show a wide range of variability in prolactin 
levels, with standard deviations ranging from 15–60 ng/mL 
and some subjects having levels  200 ng/mL. The range 
of values seen in these patients is intriguing and commands 
further investigation.
Few studies have investigated the safety and efﬁ  cacy 
of risperidone-associated prolactin elevations in pediatric 
and adolescent patient populations treated for long periods 
of time. Findling et al (2003), conducted a pooled analysis 
of 5 clinical trials which included 592 subjects 5–15 years of 
age treated with risperidone (mean = 1.25 mg/day) and had 
at least 1 post dose prolactin level drawn (Findling et al 
2003). Prolactin levels were followed over the course of 
48 weeks and found to peak at weeks 4–7. There was an 
overall 40% attrition rate over the 48-week study period, but 
in those who were followed long-term, prolactin levels at 
endpoint averaged above baseline for both genders levels of 
28.8 ± 16 ng/mL; 21.4 ± 22.7 ng/mL (for males and females 
respectively) in the 358 subjects who continued to week 48. 
Prolactin elevations of the 40% of subjects who dropped out 
were not reported.
Masi et al published a 3-year study of 53 preschool chil-
dren (4.6 ± 7 years of age) who were treated with 0.55 ± −0.2 
mg/day of risperidone (Masi et al 2003). The discontinuation 
rate was 52.8% in this study, with 22.6% due to adverse 
effects. Elevated prolactin levels occurred in 65% of subjects, 
with average levels of 28.38 ± 22.45) reported for those who 
Figure 1 Percent of subjects receiving anticholinergic medications in risperidone monotherapy trials of children and adolescents.Neuropsychiatric Disease and Treatment 2008:4(1) 65
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remained in the study (normal range for their assay was 
reported as  15 ng/mL) with elevations that exceeded 60 
ng/mL occurring in 16% of their subjects.
Saito et al conducted a prospective study of prolactin 
elevation in adolescent subjects treated with risperidone, 
olanzapine, or quetiapine for an average of 11.2 weeks (Saito 
et al 2004). Subjects treated with risperidone (mean dose = 2 
mg/day) had endpoint prolactin values of 46.8 ± 33.3 ng/mL 
with 25% of the risperidone subjects complaining of prolac-
tin-related side effects such as breast tenderness, menstrual 
irregularities, galactorrhea, or erectile dysfunction.
Finally, only 1 published study has looked at risperidone-
related prolactin increases and sexual maturation in a pooled 
analysis of 5 randomized controlled studies of children (5–15 
years of age) treated with 1.31 ± 0.70 mg/day of risperidone 
for 12 months (Dunbar et al 2004). Of the 700 children ana-
lyzed, there were no adverse outcomes at 1 year for height, 
growth, Tanner stage, or maturation. To our knowledge, data 
beyond one year have not been published.
In summary, treatment trials of children and adolescents 
show acute elevations in prolactin, which peak around 4–6 
weeks after initiation and then regress to elevated steady-state 
levels after approximately 6–8 weeks of therapy, with the 
degree of elevation being quite variable, and often occurring 
in  50% of subjects. Signiﬁ  cant elevations ( 60 ng/mL) 
are not uncommon. These long-term studies had drop-out 
rates that approached 50%, with 20%–25% of the attrition 
due to adverse effects. These reports indicate that prolactin 
increases were not associated with visible adverse effects in 
persons who did not drop out although the potential effects 
of extended periods of prolactin elevation on bone develop-
ment and homeostasis have not been deﬁ  ned and warrant 
future investigation.
Weight gain
Obesity is a growing epidemic in the United States as well as 
many other countries around the world. Obesity and weight 
gain predispose individuals to diabetes mellitus, cardio-
vascular disease, and overall increased mortality. Recent 
prevalence estimates report that from 2003–2004, 18.2% 
of males and 16.0% of females ages 2–19 in the United 
States are classiﬁ  ed as overweight (deﬁ  ned as BMI  95th 
percentile for age) (Ogden et al 2007). When this criterion 
is relaxed to also include children and adolescents at risk 
for obesity (deﬁ  ned as BMI  85th percentile for age) these 
numbers approximately double to 34.8% of males and 32.4% 
females. Children and adolescents with schizophrenia or 
bipolar disorder face additional challenges, as the majority 
of mood stabilizing agents like lithium, divalproex sodium, 
and carbamazepine and antipsychotic agents like olanzapine, 
risperidone, quetiapine, and clozapine are all associated with 
signiﬁ  cant weight gain. Recently, weight gain and metabolic 
effects in pediatric bipolar disorder were reviewed with a 
pooled analysis done on available trial data in this popula-
tion (Correll 2007). Monotherapy with second generation 
agents such as olanzapine, quetiapine, risperidone, clozapine, 
and aripiprazole resulted in an average of 3.4 kg of weight 
gained in studies lasting up to 12 weeks. Combining a mood 
stabilizing agent like lithium, lamotrigine, oxcarbazepine, or 
divalproex sodium with a second generation antipsychotic 
agent resulted in an average of 5.5 kg of weight gained.
The mechanisms behind antipsychotic-associated weight 
gain have not been fully elucidated but have been postulated 
to result from speciﬁ  c aspects of antipsychotic pharmacology 
as well as systemic effects potentially altering insulin sensi-
tivity and satiety. The second generation agents most com-
monly associated with weight gain are those with signiﬁ  cant 
antihistaminic properties, which are thought to increase thirst 
and hunger drive (Matsui-Sakata et al 2005). Among second 
generation antipsychotic agents, histamine-1 (H1) dissocia-
tion constants (Kd) have been reported to be 0.2 for olan-
zapine, 1.0 for clozapine, 6 for quetiapine, 8 for ziprasidone, 
and 12 for risperidone, with lower Kd values indicating more 
signiﬁ  cant receptor binding. Additional receptor-binding 
associated with weight gain include serotonin-2C (5HT2C) 
receptors, as well as muscarinic acetylcholine (mAch) recep-
tors (Matsui-Sakata et al 2005). Risperidone Kd values for 
mAch receptors are relatively high, with modest 5HT2C 
binding properties. Despite receptor dissociation constants 
similar to relatively weight neutral agents like ziprasidone, 
weight gain is a clinically problematic side effect for chil-
dren and adolescents taking risperidone. Weight gain, like 
EPS and prolactin elevation, is not speciﬁ  c to disease state, 
although concomitant medications that are relatively disease 
state-speciﬁ  c may inﬂ  uence the likelihood of weight gain or 
the extent of weight gained (Correll 2007).
Table 2 summarizes the weight gained in trials of 
pediatric and adolescent participants of efﬁ  cacy and effec-
tiveness trials. Selected studies of children and adolescents 
with diagnoses other than schizophrenia or bipolar disorder 
are included for comparison. Weight gained over the course 
of 6- to 12-week studies of children and adolescents with a 
variety of psychiatric disorders ranged approximately from 
1 to 8 kg. No clear relationship with dose and duration can 
be extrapolated from these studies due to heterogeneity in 
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gain through similar mechanisms, dose, or concomitant 
medications allowed in the studies. Nonetheless, the amount 
of weight gained in this short amount of time demands vigi-
lance as well as appropriate monitoring. Table 3 summarizes 
monitoring parameters developed for our Pediatric Mood 
Disorders Clinic for risperidone with other similar recom-
mendations in place for other antipsychotic agents. These 
monitoring parameters were developed to incorporate 2005 
American Psychiatric Association and American Diabetes 
Association monitoring guidelines for metabolic effects from 
second generation agents and then modiﬁ  ed to ﬁ  t the needs 
of our patient population.
Conclusion
Risperidone is a commonly used and effective medication 
for the treatment of youths with schizophrenia or bipolar 
disorders. In children and adolescents with schizophrenia, 
all of the published treatment trials have resulted in sig-
niﬁ  cant improvements in psychopathology as assessed by 
PANSS, BPRS, and CGI rating scales. Comparison trials 
with olanzapine and haloperidol have not yielded any clear 
differences in efﬁ  cacy or effectiveness between agents. In 
children and adolescents with bipolar disorder, risperidone 
is highly effective, primarily according to YMRS, BPRS, 
and CGI rating scales (as well as others); although the 
number of monotherapy trials is less than those done in the 
schizophrenia population. Doses used in the schizophrenia 
trials were on average higher than those used in the bipo-
lar studies, although the latter largely enrolled younger 
participants and often studied risperidone in combination 
with other psychotropic medicines to address common 
comorbidities.
Risperidone appears to be well-tolerated, when con-
sidering that the number of participants in these studies 
who dropped out due to adverse effects was low. However, 
somnolence, EPS, prolactin elevation, and weight gain were 
commonly observed and representative of what is seen in 
clinical practice. Somnolence is an adverse effect that often 
attenuates over time and is minimized by bed time adminis-
tration of the drug. EPS rates in these studies were relatively 
high, with 18%–67% of subjects taking  3 mg/day requiring 
an anticholinergic medication to manage these symptoms. 
Both EPS and anticholinergic medications used to manage 
them require close monitoring by clinicians, parents, and 
patients. Rates of EPS appear to be higher than with olan-
zapine although further studies need to be done to compare 
risperidone to other commonly used agents in youths like 
quetiapine, aripiprazole, and ziprasidone. EPS and tardive 
dyskinesia assessments should be done prior to beginning 
treatment, periodically during the ﬁ  rst six months of therapy 
and every 6 to 12 months thereafter.
Prolactin elevation is nearly always signiﬁ  cant in young 
patients taking risperidone, with 3- to 4-fold increases resulting 
in steady-state prolactin levels in the 30–50 ng/mL range com-
mon. However, the relationship between the extent of prolactin 
elevation and side effects is not clear and differs from patient 
to patient. The relationship of extended periods of antipsy-
chotic-associated prolactin elevation and bone development is 
Table 3 Monitoring recommendations for risperidone (modiﬁ  ed recommendations developed from ADA, APA [2004])
Measure  Baseline  1 Month  2 Months  3 Months  4 Months  Yearly
Personal/Family Hxa X          X
Vitals Every  visit
BMI (ht/wt)  Every visit
Waist circumference  X          X
Blood  pressure  X     X   X
Fasting  plasma  glucose  X     X   X
Fasting lipid proﬁ   le  X     X   X
Prolactin (a.m. preferred)b X
b     X   
LFTs X         
CBC/dif X         
Electrolytes X         
AIMS/EPS  X  Increase frequency to monthly        X
    if exhibiting signs of tardive dyskinesia
Drug interactions  X  After dose changes or when
    considering additional agents
aAssess for history of cardiovascular disease, diabetes, dyslipidemia, obesity.
bFollow-up prolactin indicated if signs of breast tenderness, gynecomastia (males), menstrual changes/irregularities (not associated with normal development), or 
galactorrhea.
Abbreviations: Hx, history; Ht, height; Wt, weight; LFTs, liver function tests; CBC/dif, complete blood count with differential.Neuropsychiatric Disease and Treatment 2008:4(1) 67
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not clear and warrants additional research. Morning prolactin 
levels should be assessed prior to treatment and again after 
six weeks of treatment to determine whether elevations are 
clinically signiﬁ  cant and warrant further evaluation.
Weight gain is also unfortunately common in risperi-
done-treated youths with increases from baseline roughly 
averaging 6–19 pounds (2.75–8.65 kg) in 6- to 12-week 
treatment trials. No clear relationship between weight gain 
and dose or treatment duration has been established, although 
the most signiﬁ  cant rates of gain appear to occur in the ﬁ  rst 
6 weeks of treatment. Weight gain along with other meta-
bolic parameters needs to be monitored closely in patients 
treated with risperidone, just as standard of practice dictates 
for other antipsychotic agents dictates (ADA, APA 2004). 
Understandably, strictly adhering to monitoring guidelines 
is not always logistically feasible due to the intricacies of the 
patient population, school schedules, etc. Therefore, we have 
developed our own monitoring guidelines for risperidone in 
our pediatric mood disorder population which is based on 
the recommendations set forth by the American Diabetes 
Association and the American Psychiatric Association, which 
are summarized in Table 3. We feel strongly that efforts to 
conduct monitoring roughly within the scope of presented 
recommendations or documentation of attempting to do so is 
clinically prudent to ensure the long term safety of patients 
as best as possible.
Risperidone is therefore a widely used and effective medi-
cation for the treatment of schizophrenia and bipolar disorders 
in youths. Additional research needs to be conducted to assess 
comparisons with other second generation antipsychotic medi-
cations that are also treatment options. Monitoring and coun-
seling on common side effects from risperidone is essential, 
just as it is with other medications. Future research on clinical 
and biological predictors of treatment response and side effect 
risk will allow us to optimize treatments with antipsychotic 
agents in these populations to further optimize the risk beneﬁ  t 
ratio in the treatment of these hard-to-treat patients.
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